Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

KRT14 Antibodies

Cytokeratin 14 (CK14), encoded by the KRT14 gene on chromosome 17q21.2, is a type I intermediate filament protein. It consists of 472 amino acids and has a molecular weight of approximately 50 kDa. CK14 undergoes various post-translational modifications, including phosphorylation, glycosylation, and formation of disulfide bonds. These modifications can modulate its stability, localization, and function within cells. CK14 is primarily an intracellular protein, serving as a structural component of the cytoskeleton, particularly in epithelial cells. It is prominently expressed in basal epithelial cells of the skin, oral cavity, esophagus, and urogenital tract. Various factors, including developmental signals, tissue-specific transcription factors, and hormonal influences, regulate the expression of CK14.

CK14 has been implicated in several health conditions and diseases. Notably, mutations in the KRT14 gene are associated with certain types of epidermolysis bullosa, a group of genetic disorders characterized by skin fragility and blistering. Furthermore, aberrant expression of CK14 has been observed in various epithelial tumors, including basal-like breast cancer, squamous cell carcinoma, and some types of head and neck cancers.

CK14 expression has been shown to have diagnostic and prognostic value in certain cancers and diseases. For example, in breast cancer, CK14 expression is associated with the basal-like subtype, which tends to have a more aggressive clinical course and poorer prognosis compared to other subtypes. In this sense, measuring CK14 expression can help classify breast tumors and guide treatment decisions. In squamous cell carcinoma of the head and neck, CK14 expression has been linked to more aggressive tumor behavior and poorer patient outcomes. Furthermore, CK14 expression can also be informative in diagnosing certain skin disorders, such as epidermolysis bullosa. Detection of CK14 expression in skin biopsies can assist in confirming the diagnosis of this condition.

NeoBiotechnologies offers a variety of antibodies against CK14 that have been validated for ELISA, flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting, as well as HuProt-validated options. Additionally, we hold exclusive rights to CK14 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/page/2/?s=KRT14].


Keratin, type I cytoskeletal 14, Cytokeratin-14, Keratin-14, CK-14; Dowling Meara; ebs3; ebs4; Epidermolysis Bullosa Simplex; k14; Keratin 14; Keratin Type I Cytoskeletal 14; Koebner; krt14; NFJ

Research Areas

Developmental Biology, Basal Cell Marker

Showing 1–25 of 28 results


Showing 1–25 of 28 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.